Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vaxcyte, Inc. - Common Stock
(NQ:
PCVX
)
66.02
-0.69 (-1.03%)
Delayed Quote
Updated: 1:00 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vaxcyte, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
↗
October 05, 2026
Vaxcyte (NASDAQ:PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults....
Via
MarketBeat
Keep an eye on the top gainers and losers in Monday's session.
↗
October 05, 2026
Via
Chartmill
Monday's session: gap up and gap down stocks
↗
October 05, 2026
Via
Chartmill
Discover the top movers in Monday's pre-market session.
↗
October 05, 2026
Via
Chartmill
Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position
↗
February 24, 2026
Via
Chartmill
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
↗
September 08, 2026
Guggenhime surrendered shares to cover tax withholding on vesting RSUs, retaining about 164,000 shares valued at $10.12 million.
Via
The Motley Fool
Topics
Regulatory Compliance
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
↗
September 08, 2026
Wassil exercised options at a steep discount and surrendered shares for tax withholding, maintaining a 0.1% ownership stake following the transactions.
Via
The Motley Fool
Topics
Regulatory Compliance
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
↗
September 08, 2026
The stock has surged 95% over the past year, and the CEO retains about 447,000 direct shares plus indirect holdings.
Via
The Motley Fool
Topics
Regulatory Compliance
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
↗
June 03, 2026
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
↗
May 24, 2026
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
↗
May 24, 2026
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
↗
May 19, 2026
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
Via
The Motley Fool
Topics
Regulatory Compliance
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
↗
May 19, 2026
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
↗
May 18, 2026
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
↗
March 21, 2026
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
↗
March 21, 2026
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
↗
March 21, 2026
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
↗
March 21, 2026
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
Via
The Motley Fool
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
March 09, 2026
As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Vaxcyte's Chief Technical Ops Officer Sells Shares
↗
January 03, 2026
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.
Via
The Motley Fool
Topics
Regulatory Compliance
These 3 Stocks Are Using Buybacks to Signal Market Confidence
↗
November 18, 2025
Via
MarketBeat
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown
↗
September 30, 2025
Thermo Fisher sells four-part dollar bonds as U.S. investment-grade issuance tops $200 billion, with yields near historic lows and spreads tight.
Via
Benzinga
Topics
Bonds
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data
↗
September 11, 2025
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.
Via
Benzinga
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
August 07, 2025
Via
Benzinga
Vaxcyte (PCVX) Q2 Loss Widens 11%
↗
August 06, 2025
Via
The Motley Fool
Topics
Intellectual Property
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
April 01, 2025
Via
Benzinga
Top stock movements in today's session.
↗
March 31, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
Monday's session: top gainers and losers
↗
March 31, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
March 31, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
March 31, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
